YORK, Pa. , Nov. 11, 2013 -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a U.S. based designer, developer and manufacturer of injectable drug delivery systems, today announced an agreement with MedImmune , the global biologics research and development arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors for use with molecules in MedImmune's pipeline.
Under this agreement,
Mr.
"We are pleased that
The wearable injection category is expected to generate device sales in excess of
Conference Call Information
About the ReadyToGo Wearable Injectors
The
The ReadyToGo wearable injectors are designed for integration with standard filling processes, utilize standard materials in the primary drug container and require no terminal sterilization. A fully programmable delivery regimen allows the bolus, basal or variable rate of dose delivery to be customized to specific customer, therapy and patient requirements. The electronics in the device can be easily detached and disposed for markets that require special electronics disposal procedures. A video of
About
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the
General: UNIS-G
Investor and PR Contacts (US): |
Analyst Enquiries |
Investor Contacts ( |
|
Lynn Pieper |
Jeff Carter |
KCSA Strategic Communications |
Westwicke Partners |
Unilife Corporation |
P: + 1 212-682-6300 |
P: + 1 415-202-5678 |
P: + 61 2 8346 6500 |
SOURCE